Online first
Original research article
Published online: 2025-03-25
Hematopoietic stem cell transplantation in children with inborn errors of metabolism - experience of Polish Pediatric Stem Cell Transplantation Group
1
, 2, 2, 2, 1, 3, 3, 4, 4, 5, 3
, 2, 2, 2, 1, 3, 3, 4, 4, 5, 3
DOI: 10.5603/ahp.102954
Abstract
Over the years HSCT has become a standard treatment option for selected inborn error of metabolism (IEM), while the transplant program for metabolic diseases in Poland has gradually developed. This study analyzed data from 75 HSCT procedures of 65 pediatric patients with IEM, performed between 2001 and 2022 in pediatric bone marrow transplantation centers of Poznan, Cracow, Wroclaw, and Lublin. The results showed that overall survival (OS) was significantly higher in patients transplanted after 2010 (85.11%. vs 55.56%; p=0.04). A similar trend was observed in the group with standard indications for HSCT (81.63% vs 62.5%), although the difference was not statistically significant (p=0.07). Other assessed parameters, such as the source of transplanted stem cells and the choice of conditioning regime had no statistically significant impact on patients’ OS. Achieved chimerism, engraftment, and causes of treatment failure were also analyzed in this paper. In comparison between Polish transplantation centers and foreign units, the effectiveness of treatment was on a comparable level. While fewer patients with IEM are referred to transplantation in Poland compared to most European countries, this paper aims to inform healthcare professionals about the availability of the HSCT procedure for IEM patients.
Keywords: Inborn errors of metabolismHematopoietic stem cell transplantationMetabolic diseases
References
- Snowden JA, Sánchez-Ortega I, Corbacioglu S, et al. European Society for Blood and Marrow Transplantation (EBMT). Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transplant. 2022; 57(8): 1217–1239.
- Wynn R, Schulz A. Inborn Errors of Metabolism and Osteopetrosis. The EBMT Handbook. 2018: 671–676.
- Gentner B, Tucci F, Galimberti S, et al. MPSI Study Group. Hematopoietic Stem- and Progenitor-Cell Gene Therapy for Hurler Syndrome. N Engl J Med. 2021; 385(21): 1929–1940.
- Gujral J, Sethuram S. An update on the diagnosis and treatment of adrenoleukodystrophy. Curr Opin Endocrinol Diabetes Obes. 2023; 30(1): 44–51.
- Boelens JJ, Wynn RF, O'Meara A, et al. Outcomes of hematopoietic stem cell transplantation for Hurler's syndrome in Europe: a risk factor analysis for graft failure. Bone Marrow Transplant. 2007; 40(3): 225–233.
- Nan H, Park C, Maeng S. Mucopolysaccharidoses I and II: Brief Review of Therapeutic Options and Supportive/Palliative Therapies. Biomed Res Int. 2020; 2020: 2408402.
- Lamichhane A, Cabrero FR. Metachromatic Leukodystrophy. In StatPearls [internet]. Treasure Island (FL): StatPearls Publishing 2023. https://www.ncbi.nlm.nih.gov/books/NBK560744/.
- Orchard PJ, Fasth AL, Le Rademacher J, et al. Hematopoietic stem cell transplantation for infantile osteopetrosis. Blood. 2015; 126(2): 270–276.
- Passweg JR, Baldomero H, Ciceri F, et al. Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT. Bone Marrow Transplant. 2024; 59(6): 803–812.
- Wachowiak J, Chybicka A, Kowalczyk JR, et al. Development and current use of in hematopoietic stem cell transplantation in children and adolescents in Poland: Report of the Polish pediatric study group for hematopoietic stem cell transplantation of the Polish society for pediatric oncology and hematology. Transfus Apher Sci. 2018; 57(3): 316–322.
- Wynn R. Stem cell transplantation in inherited metabolic disorders. Hematology Am Soc Hematol Educ Program. 2011; 2011: 285–291.
- Boelens JJ. Trends in haematopoietic cell transplantation for inborn errors of metabolism. J Inherit Metab Dis. 2006; 29(2-3): 413–420.
- Hampe CS, Wesley J, Lund TC, et al. Mucopolysaccharidosis Type I: Current Treatments, Limitations, and Prospects for Improvement. Biomolecules. 2021; 11(2).
- Beschle J, Döring M, Kehrer C, et al. Early clinical course after hematopoietic stem cell transplantation in children with juvenile metachromatic leukodystrophy. Mol Cell Pediatr. 2020; 7(1): 12.
- Clarke LA, Dickson P, Ellinwood NM, et al. Newborn Screening for Mucopolysaccharidosis I: Moving Forward Learning from Experience. Int J Neonatal Screen. 2020; 6(4).
- Burton BK, Shively V, Quadri A, et al. Newborn screening for mucopolysaccharidosis type II: Lessons learned. Mol Genet Metab. 2023; 140(1-2): 107557.
- Boelens JJ, Aldenhoven M, Purtill D, et al. Eurocord, Inborn Errors Working Party of European Blood and Marrow Transplant group, Duke University Blood and Marrow Transplantation Program, Centre for International Blood and Marrow Research. Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning. Blood. 2013; 121(19): 3981–3987.
- van den Broek BTA, Page K, Paviglianiti A, et al. Early and late outcomes after cord blood transplantation for pediatric patients with inherited leukodystrophies. Blood Adv. 2018; 2(1): 49–60.
- Qu Y, Liu H, Wei L, et al. The Outcome of Allogeneic Hematopoietic Stem Cell Transplantation From Different Donors in Recipients With Mucopolysaccharidosis. Front Pediatr. 2022; 10: 877735.
- Sreekantam S, Smith L, Stewart C, et al. Efficacy of early haematopoietic stem cell transplantation versus enzyme replacement therapy on neurological progression in severe Hunter syndrome: Case report of siblings and literature review. Mol Genet Metab Rep. 2022; 32: 100881.
- Kato S, Yabe H, Takakura H, et al. Hematopoietic stem cell transplantation for inborn errors of metabolism: A report from the Research Committee on Transplantation for Inborn Errors of Metabolism of the Japanese Ministry of Health, Labour and Welfare and the Working Group of the Japan Society for Hematopoietic Cell Transplantation. Pediatr Transplant. 2016; 20(2): 203–214.
- Bradbury AM, Bongarzone ER, Sands MS. Krabbe disease: New hope for an old disease. Neurosci Lett. 2021; 752: 135841.
- Leal AF, Benincore-Flórez E, Solano-Galarza D, et al. GM2 Gangliosidoses: Clinical Features, Pathophysiological Aspects, and Current Therapies. Int J Mol Sci. 2020; 21(17).
- Ceccarini MR, Codini M, Conte C, et al. Alpha-Mannosidosis: Therapeutic Strategies. Int J Mol Sci. 2018; 19(5).
- Jeyaratnam J, Faraci M, Gennery AR, et al. EBMT Inborn Errors Working Party. The efficacy and safety of allogeneic stem cell transplantation in Mevalonate Kinase Deficiency. Pediatr Rheumatol Online J. 2022; 20(1): 56.
- Osorio MJ, Rowitch DH, Tesar P, et al. Concise Review: Stem Cell-Based Treatment of Pelizaeus-Merzbacher Disease. Stem Cells. 2017; 35(2): 311–315.
- Sykora KW, Beier R, Schulz A, et al. Treosulfan vs busulfan conditioning for allogeneic bmt in children with nonmalignant disease: a randomized phase 2 trial. Bone Marrow Transplant. 2024; 59(1): 107–116.
- Chiesa R, Boelens JJ, Duncan CN, et al. Variables affecting outcomes after allogeneic hematopoietic stem cell transplant for cerebral adrenoleukodystrophy. Blood Adv. 2022; 6(5): 1512–1524.
- Tan EY, Boelens JJ, Jones SA, et al. Hematopoietic Stem Cell Transplantation in Inborn Errors of Metabolism. Front Pediatr. 2019; 7: 433.
- DeFilipp Z, Hefazi M, Chen YB, et al. Emerging approaches to improve allogeneic hematopoietic cell transplantation outcomes for nonmalignant diseases. Blood. 2022; 139(25): 3583–3593.
- Page KM, Stenger EO, Connelly JA, et al. Hematopoietic Stem Cell Transplantation to Treat Leukodystrophies: Clinical Practice Guidelines from the Hunter's Hope Leukodystrophy Care Network. Biol Blood Marrow Transplant. 2019; 25(12): e363–e374.
- Engelen M, Kemp S, de Visser M, et al. X-linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up and management. Orphanet J Rare Dis. 2012; 7: 51.
- Engelen M, Kemp S, Poll-The BT. X-linked adrenoleukodystrophy: pathogenesis and treatment. Curr Neurol Neurosci Rep. 2014; 14(10): 486.
- Wu CC, Econs MJ, DiMeglio LA, et al. Diagnosis and Management of Osteopetrosis: Consensus Guidelines From the Osteopetrosis Working Group. J Clin Endocrinol Metab. 2017; 102(9): 3111–3123.
- Maurizi A. Experimental therapies for osteopetrosis. Bone. 2022; 165: 116567.
- Eichler F, Duncan C, Musolino PL, et al. Hematopoietic Stem-Cell Gene Therapy for Cerebral Adrenoleukodystrophy. N Engl J Med. 2017; 377(17): 1630–1638.
- Das S, Rruga F, Montepeloso A, et al. An empowered, clinically viable hematopoietic stem cell gene therapy for the treatment of multisystemic mucopolysaccharidosis type II. Mol Ther. 2024; 32(3): 619–636.
- Fumagalli F, Calbi V, Natali Sora MG, et al. Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1/2 trial and expanded access. Lancet. 2022; 399(10322): 372–383.
- Moscatelli I, Almarza E, Schambach A, et al. Gene therapy for infantile malignant osteopetrosis: review of pre-clinical research and proof-of-concept for phenotypic reversal. Mol Ther Methods Clin Dev. 2021; 20: 389–397.
- Lauer A, Speroni SL, Choi M, et al. Hematopoietic stem-cell gene therapy is associated with restored white matter microvascular function in cerebral adrenoleukodystrophy. Nat Commun. 2023; 14(1): 1900.